Over the last few months I am sure you’ve heard more and more regarding PPCH and their latest developments in the fight against pancreatic cancer. It’s an exciting time as this biopharmaceutical company reaches the clinical development stage of its new cancer treatment, PRP, for patients suffering from solid tumors like pancreatic, ovarian and colorectal cancers.


Last week, Propanc’s Chief Executive Officer, James Nathanielsz, was interviewed on SmallCapVoice.com. Investors and medical professionals alike should tune into this interview for highlights on their history, the markets they serve, their business model, where the company stands today, and the goals for the remainder of their most successful year to date.

In this exclusive interview, Nathanielsz discusses how the company formed in Australia in 2007 and went public in the United States in 2012. Over the last few years, the company has built its extensive international network of international research partners and is currently on track towards its First-In-Human study for PRP. The interviewer points out that PPCH’s website is thorough and easy to navigate. Their recent video release makes it easy to understand how PRP works without having to be an expert in biochemistry. Their team did an excellent job producing a video that can be understood by professionals across the investor and finance industry. The video is titled “Mechanism of Action” and can be viewed by following this link: http://www.propanc.com/news-media/video. PRP reprograms cancer stem cells so that they are no longer malignant and a threat to the patient.

“Right now, based on all the information we’ve been able to generate and the scientific data that supports our efforts, what we’re really focused on is two key aspects for the Company and they are quite simple: One, get this product to patients as soon as possible. Two, if it works, get it to as many patients as possible.” –Nathanielsz, CEO.

It might be wise to keep up with what’s happening with PPCH and their lead product, PRP, as 2017 progresses. For the full interview with Nathanielsz click on this link: http://smallcapvoice.com/blog/5-19-17-smallcapvoice-interview-with-propanc-biopharma-inc-ppch


Cleveland BioLabs (CBIO) completed a clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in 40 treatment-naïve patients with primary colorectal cancer recommended for surgery. This study was conducted in Russia and partially funded by the development contract with the MPT.

Shares of small cap biotech firm Neuroderm (NDRM) have been looking pretty strong, rising almost 50% in the past year and over 20% year to date. Management estimates over 350,000 severe Parkinson’s disease patients in the US and EU eligible for treatment, while the moderate PD market equates to over 900,000 patients in both regions combined.

Aurinia Pharmaceuticals Inc. (AUPH), a clinical stage biopharmaceutical company focused on the global immunology market, announced it’s been selected to present late breaking oral presentations at both the 54th European Renal Association-European Dialysis and Transplant Association’s (ERA-EDTA) Congress and the Annual European Congress of Rheumatology (EULAR) 2017, on June 3th-6th, 2017, Madrid, Spain and June 14-17, Madrid, Spain, respectively.

Achillion Pharmaceuticals (ACHN) is scheduled to present two abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/